These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36719280)

  • 61. Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria.
    Bada FO; Blok N; Okpokoro E; Dutt S; Akolo C; Dakum P; Abimiku A
    PLoS One; 2020; 15(12):e0241065. PubMed ID: 33259492
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Multidrug-resistant tuberculosis in the Kharkiv Region, Ukraine.
    Butov D; Lange C; Heyckendorf J; Kalmykova I; Butova T; Borovok N; Novokhatskaya M; Chesov D
    Int J Tuberc Lung Dis; 2020 May; 24(5):485-491. PubMed ID: 32398197
    [No Abstract]   [Full Text] [Related]  

  • 63. In vitro synergistic activity of clofazimine and other antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis isolates.
    Zhang Z; Li T; Qu G; Pang Y; Zhao Y
    Int J Antimicrob Agents; 2015 Jan; 45(1):71-5. PubMed ID: 25459737
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Bedaquiline and delamanid in the treatment of multidrug-resistant tuberculosis: Promising but challenging.
    Li Y; Sun F; Zhang W
    Drug Dev Res; 2019 Feb; 80(1):98-105. PubMed ID: 30548290
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs.
    Huerga H; Khan U; Bastard M; Mitnick CD; Lachenal N; Khan PY; Seung KJ; Melikyan N; Ahmed S; Rich ML; Varaine F; Osso E; Rashitov M; Salahuddin N; Salia G; Sánchez E; Serobyan A; Rafi Siddiqui M; Grium Tefera D; Vetushko D; Yeghiazaryan L; Holtzman D; Islam S; Kumsa A; Jacques Leblanc G; Leonovich O; Mamsa S; Manzur-Ul-Alam M; Myint Z; Padayachee S; Franke MF; Hewison C
    Clin Infect Dis; 2022 Oct; 75(8):1307-1314. PubMed ID: 35243494
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Initial experience of bedaquiline implementation under the National TB Programme at NITRD, Delhi, India.
    Sarin R; Singla N; Vohra V; Singla R; Puri MM; Munjal S; Khalid UK; Myneedu VP; Kumar Verma A; Mathuria KK
    Indian J Tuberc; 2019 Jan; 66(1):209-213. PubMed ID: 30878071
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Development and Validation of a Nomogram for Prediction of QT Interval Prolongation in Patients Administered Bedaquiline-Containing Regimens in China: a Modeling Study.
    Liu F; Gao J; Gao M; Liu Y; Shu W; Xie L; Sun Y; Zhang L; Li L; Pang Y
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0203321. PubMed ID: 36047781
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Dose-related adverse events in South African patients prescribed clofazimine for drug-resistant tuberculosis.
    Misra N; Padayatchi N; Naidoo P
    S Afr Med J; 2019 Dec; 110(1):32-37. PubMed ID: 31865940
    [TBL] [Abstract][Full Text] [Related]  

  • 69. New Drugs and Regimens for Tuberculosis Disease Treatment in Children and Adolescents.
    Garcia-Prats AJ; Starke JR; Waning B; Kaiser B; Seddon JA
    J Pediatric Infect Dis Soc; 2022 Oct; 11(Supplement_3):S101-S109. PubMed ID: 36314547
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis.
    Achar J; Hewison C; Cavalheiro AP; Skrahina A; Cajazeiro J; Nargiza P; Herboczek K; Rajabov AS; Hughes J; Ferlazzo G; Seddon JA; du Cros P
    Emerg Infect Dis; 2017 Oct; 23(10):1711-3. PubMed ID: 28758889
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Improved Treatment Outcomes With Bedaquiline When Substituted for Second-line Injectable Agents in Multidrug-resistant Tuberculosis: A Retrospective Cohort Study.
    Zhao Y; Fox T; Manning K; Stewart A; Tiffin N; Khomo N; Leslie J; Boulle A; Mudaly V; Kock Y; Meintjes G; Wasserman S
    Clin Infect Dis; 2019 Apr; 68(9):1522-1529. PubMed ID: 30165431
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Impacts of clofazimine on the treatment outcomes of drug-resistant tuberculosis.
    Wang MG; Liu XM; Wu SQ; He JQ
    Microbes Infect; 2023; 25(1-2):105020. PubMed ID: 35792202
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Additional Drug Resistance in Patients with Multidrug-resistant Tuberculosis in Korea: a Multicenter Study from 2010 to 2019.
    Lee T; Lee SJ; Jeon D; Lee HY; Kim HJ; Kang BH; Mok J
    J Korean Med Sci; 2021 Jul; 36(26):e174. PubMed ID: 34227261
    [TBL] [Abstract][Full Text] [Related]  

  • 74. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon.
    Kuaban C; Noeske J; Rieder HL; Aït-Khaled N; Abena Foe JL; Trébucq A
    Int J Tuberc Lung Dis; 2015 May; 19(5):517-24. PubMed ID: 25868018
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis.
    Ding Y; Zhu H; Fu L; Zhang W; Wang B; Guo S; Chen X; Wang N; Liu H; Lu Y
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0065822. PubMed ID: 35924925
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study.
    Franke MF; Khan P; Hewison C; Khan U; Huerga H; Seung KJ; Rich ML; Zarli K; Samieva N; Oyewusi L; Nair P; Mudassar M; Melikyan N; Lenggogeni P; Lecca L; Kumsa A; Khan M; Islam S; Hussein K; Docteur W; Chumburidze N; Berikova E; Atshemyan H; Atwood S; Alam M; Ahmed S; Bastard M; Mitnick CD
    Am J Respir Crit Care Med; 2021 Jan; 203(1):111-119. PubMed ID: 32706644
    [No Abstract]   [Full Text] [Related]  

  • 77. Effectiveness of Shorter Treatment Regimen in Multidrug-Resistant Tuberculosis Patients in Pakistan: A Multicenter Retrospective Record Review.
    Wahid A; Ahmad N; Ghafoor A; Latif A; Saleem F; Khan S; Atif M; Iqbal Q
    Am J Trop Med Hyg; 2021 Mar; 104(5):1784-1791. PubMed ID: 33724924
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis.
    Mbuagbaw L; Guglielmetti L; Hewison C; Bakare N; Bastard M; Caumes E; Fréchet-Jachym M; Robert J; Veziris N; Khachatryan N; Kotrikadze T; Hayrapetyan A; Avaliani Z; Schünemann HJ; Lienhardt C
    Emerg Infect Dis; 2019 May; 25(5):936-943. PubMed ID: 31002070
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study.
    Ndjeka N; Campbell JR; Meintjes G; Maartens G; Schaaf HS; Hughes J; Padanilam X; Reuter A; Romero R; Ismail F; Enwerem M; Ferreira H; Conradie F; Naidoo K; Menzies D
    Lancet Infect Dis; 2022 Jul; 22(7):1042-1051. PubMed ID: 35512718
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline.
    Diacon AH; Dawson R; von Groote-Bidlingmaier F; Symons G; Venter A; Donald PR; van Niekerk C; Everitt D; Hutchings J; Burger DA; Schall R; Mendel CM
    Am J Respir Crit Care Med; 2015 Apr; 191(8):943-53. PubMed ID: 25622149
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.